| | | |   | | | | By Ed Silverman Adobe Skinny labeling on biosimilar drugs saved Medicare $1.5 billion between 2015 and 2020 on just five medicines during that period. Read More | | By Allison DeAngelis Adobe The Alzheimer's therapy, AXS-05, met its primary goal of delaying time to relapse and preventing patients from relapsing. Read More | | By Matthew Herper STAT In a wide-ranging interview at the STAT Summit, Ken Frazier reflected on the past and looked toward the future. Read More | | Sponsored Insight by STAT TRIALS PULSE Could warning signs in Summit Therapeutics' clinical trial activity have hinted at bad results months before they were announced? There are an average of over 6,800 clinical trials updates every day. Trying to analyze these changes and identify patterns is a staggering but essential undertaking for life sciences professionals seeking competitive intelligence. That's where STAT Trials Pulse steps in. We connect disparate sources of clinical trials data, detect important updates, and add context to deliver a curated stream of actionable alerts. Learn more at statnews.com/trials-pulse, or start your 30-day free trial.
| | By Ryan Cross — The Boston Globe Doug Levy/AP Buoyed by the success of the COVID-19 shots, biotech startups are hoping to expand the reach of mRNA medicines into cancer. Read More | | By Madhav Thambisetty Adobe Brain shrinkage, observed in trials of anti-amyloid antibodies used to treat Alzheimer's disease, needs closer scrutiny. Read More | |
No comments